Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984206761> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- W1984206761 endingPage "229" @default.
- W1984206761 startingPage "220" @default.
- W1984206761 abstract "<b><i>Introduction:</i></b> We evaluated the effectiveness of natalizumab in patients with highly active, relapsing-remitting multiple sclerosis (HA-RRMS) to identify baseline predictors associated with freedom from disease activity. <b><i>Methods:</i></b> We analyzed 70 patients treated with natalizumab and followed for at least 1 year with progression of disability of ≥1 point on the EDSS before starting therapy. We recorded freedom from clinical activity, radiological activity, and disease activity (clinical and radiological). <b><i>Results:</i></b> The median (IQR) follow-up was 2.3 (2.0-3.8) years. Of the 52 patients who completed 2 years of treatment, 25 were free of disease activity (48.1%). The ARR decreased from a mean ± SD of 2.49 ± 0.86 at baseline to 0.47 ± 0.83 at the end of the first year (p < 0.001) and 0.34 ± 0.69 at the end of the second year (p < 0.001). The percentage of patients with gadolinium-enhanced lesions decreased from 21 at baseline to 5.7 at the end of the first year (p < 0.001) and to 5.8 during the second year (p < 0.005). Baseline EDSS ≤3.0 was significantly associated with freedom from disease activity (OR, 2.49; 95% CI, 1.24-4.99; p = 0.010). <b><i>Conclusions:</i></b> Natalizumab is effective in patients with HA-RRMS. Baseline EDSS ≤3.0 increases the probability of remaining disease-free in HA-RRMS treated with natalizumab." @default.
- W1984206761 created "2016-06-24" @default.
- W1984206761 creator A5028243696 @default.
- W1984206761 creator A5038786269 @default.
- W1984206761 creator A5043464032 @default.
- W1984206761 creator A5050227560 @default.
- W1984206761 creator A5055129267 @default.
- W1984206761 creator A5063748845 @default.
- W1984206761 creator A5082895881 @default.
- W1984206761 date "2015-01-01" @default.
- W1984206761 modified "2023-10-16" @default.
- W1984206761 title "Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis" @default.
- W1984206761 cites W1514064771 @default.
- W1984206761 cites W1905950082 @default.
- W1984206761 cites W1964291413 @default.
- W1984206761 cites W1964558929 @default.
- W1984206761 cites W1986598933 @default.
- W1984206761 cites W1998134625 @default.
- W1984206761 cites W2015146080 @default.
- W1984206761 cites W2046493046 @default.
- W1984206761 cites W2061762188 @default.
- W1984206761 cites W2068638773 @default.
- W1984206761 cites W2083237321 @default.
- W1984206761 cites W2103758700 @default.
- W1984206761 cites W2105053272 @default.
- W1984206761 cites W2105159132 @default.
- W1984206761 cites W2122545833 @default.
- W1984206761 cites W2127001605 @default.
- W1984206761 cites W2129586747 @default.
- W1984206761 cites W2130355701 @default.
- W1984206761 cites W2136756445 @default.
- W1984206761 cites W2147062889 @default.
- W1984206761 cites W2158338004 @default.
- W1984206761 doi "https://doi.org/10.1159/000375371" @default.
- W1984206761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25792347" @default.
- W1984206761 hasPublicationYear "2015" @default.
- W1984206761 type Work @default.
- W1984206761 sameAs 1984206761 @default.
- W1984206761 citedByCount "10" @default.
- W1984206761 countsByYear W19842067612015 @default.
- W1984206761 countsByYear W19842067612016 @default.
- W1984206761 countsByYear W19842067612017 @default.
- W1984206761 countsByYear W19842067612019 @default.
- W1984206761 countsByYear W19842067612020 @default.
- W1984206761 countsByYear W19842067612021 @default.
- W1984206761 crossrefType "journal-article" @default.
- W1984206761 hasAuthorship W1984206761A5028243696 @default.
- W1984206761 hasAuthorship W1984206761A5038786269 @default.
- W1984206761 hasAuthorship W1984206761A5043464032 @default.
- W1984206761 hasAuthorship W1984206761A5050227560 @default.
- W1984206761 hasAuthorship W1984206761A5055129267 @default.
- W1984206761 hasAuthorship W1984206761A5063748845 @default.
- W1984206761 hasAuthorship W1984206761A5082895881 @default.
- W1984206761 hasConcept C126322002 @default.
- W1984206761 hasConcept C203014093 @default.
- W1984206761 hasConcept C2780640218 @default.
- W1984206761 hasConcept C2780892749 @default.
- W1984206761 hasConcept C2781004633 @default.
- W1984206761 hasConcept C3020694758 @default.
- W1984206761 hasConcept C71924100 @default.
- W1984206761 hasConcept C90924648 @default.
- W1984206761 hasConceptScore W1984206761C126322002 @default.
- W1984206761 hasConceptScore W1984206761C203014093 @default.
- W1984206761 hasConceptScore W1984206761C2780640218 @default.
- W1984206761 hasConceptScore W1984206761C2780892749 @default.
- W1984206761 hasConceptScore W1984206761C2781004633 @default.
- W1984206761 hasConceptScore W1984206761C3020694758 @default.
- W1984206761 hasConceptScore W1984206761C71924100 @default.
- W1984206761 hasConceptScore W1984206761C90924648 @default.
- W1984206761 hasIssue "3-4" @default.
- W1984206761 hasLocation W19842067611 @default.
- W1984206761 hasOpenAccess W1984206761 @default.
- W1984206761 hasPrimaryLocation W19842067611 @default.
- W1984206761 hasRelatedWork W1978839861 @default.
- W1984206761 hasRelatedWork W1984206761 @default.
- W1984206761 hasRelatedWork W2000175930 @default.
- W1984206761 hasRelatedWork W2014391919 @default.
- W1984206761 hasRelatedWork W2108212495 @default.
- W1984206761 hasRelatedWork W2149933470 @default.
- W1984206761 hasRelatedWork W2405536231 @default.
- W1984206761 hasRelatedWork W2525470836 @default.
- W1984206761 hasRelatedWork W2895348378 @default.
- W1984206761 hasRelatedWork W4283270450 @default.
- W1984206761 hasVolume "73" @default.
- W1984206761 isParatext "false" @default.
- W1984206761 isRetracted "false" @default.
- W1984206761 magId "1984206761" @default.
- W1984206761 workType "article" @default.